Local DHEA and Estradiol on Dyspareunia in Postmenopausal Women
Effects of Local Dehydroepiandrosterone (DHEA) and Estradiol on Moderate to Severe Dyspareunia, a Symptom of Vulvovaginal Atrophy in Postmenopausal Women - a Randomized, Controlled Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Angelica L Hirschberg, MD, PhD
- Phone Number: +46 70 255 99 24
- Email: angelica.linden-hirschberg@regionstockholm.se
Study Locations
-
-
-
Stockholm, Sweden, 171 76
- Karolinska University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Postmenopausal women (non-hysterectomized or hysterectomized) must satisfy either: a) No menses for at least one year for non-hysterectomized women, or b) Follicle stimulating hormone (FSH) levels >40 IU/L
- Women who have self-identified at screening and baseline (Day 1) as experiencing moderate to severe dyspareunia, using VASQ questionnaire (section 1)
- Between 40 and 80 years of age
- Body mass index (BMI) 19-35
- Women having a vaginal pH above 5 at screening and baseline (Day 1)
- Women who currently have intercourse or other sexual activity, at least once a month, with a partner
- Normal mammogram within 12 months (of Day 1)
- A normal PAP smear (which includes inflammatory changes) within the last 12 months (of Day 1) for both non-hysterectomized and hysterectomized women.
- Understands Swedish and is willing to participate in the study and sign an informed consent
Exclusion Criteria:
- Undiagnosed abnormal vaginal bleeding
- Previous diagnosis of cancer, except skin cancer (non-melanoma)
- Lichen Sclerosis and other pathological conditions in vulva and/or vagina
- Active or history of thromboembolic disease
- Clinically significant metabolic or endocrine disease (including diabetes mellitus) not controlled by medication
- Oral estrogen, progestin or DHEA exposure or intrauterine progestin therapy in the 8 weeks prior to baseline assessments (screening visit)
- Vaginal hormonal products (rings, creams, gels or tablets) or transdermal estrogen alone or estrogen/progestin products in the 4 weeks prior to baseline assessments (screening visit)
- Use of testosterone or other anabolic steroid within 6 months prior to screening visit
- Natural oral estrogenic products in the 4 weeks prior to baseline assessments
- Confirmed clinically significant depression (not controlled by standard therapy) or confirmed history of severe psychiatric disturbance
- The administration of any investigational drug within 30 days of screening visit
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Vaginal estradiol 10 μg
|
Vagifem® (estradiol), vaginal tablets
|
|
Active Comparator: Vaginal DHEA 6,5 mg
|
Intrarosa® (dehydroepiandrosterone; DHEA; prasterone), pessaries
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dyspareunia, a symptom of VVA in postmenopausal women
Time Frame: Primary endpoint will be evaluated as change in dyspareunia (VASQ section 1) from baseline to Week 12
|
Patient reports in the Vaginal Atrophy Symptoms Questionnaire (VASQ, section 1).
A 4-point scale, where a higher point means more symptoms.
|
Primary endpoint will be evaluated as change in dyspareunia (VASQ section 1) from baseline to Week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total symptom score of VVA
Time Frame: Change from baseline to Week 4 and 12
|
Vaginal dryness and irritation/itching (VASQ, section 2 and 3, a 4-point scale, where a higher point means more symptoms)
|
Change from baseline to Week 4 and 12
|
|
Clinical signs of VVA
Time Frame: Change from baseline to Week 4 and 12
|
Examination of vaginal atrophy symptoms (VAX).
A 4-point scale, where a higher point means more symptoms.
|
Change from baseline to Week 4 and 12
|
|
Sexual function
Time Frame: Change from baseline to Week 4 and 12
|
Profile of Female Sexual Function (PFSF) and its seven domains desire, arousal, orgasm, pleasure, concern, responsiveness and self-image (range from 0 to 100, where a lower score means more dysfunction)
|
Change from baseline to Week 4 and 12
|
|
Urinary incontinence
Time Frame: Change from baseline to Week 4 and 12
|
The Incontinence Impact Questionnaire (IIQ-7, a 4-point scale, where a higher point means more symptoms)
|
Change from baseline to Week 4 and 12
|
|
Histomorphology of the vaginal wall
Time Frame: Change from baseline to Week 4 and 12
|
Histomorphology (thickness of epithelium, lamina propria and muscle layer in vaginal biopsies)
|
Change from baseline to Week 4 and 12
|
|
Sex hormone levels
Time Frame: Change from baseline to Week 4 and 12
|
Sex hormone levels (estradiol and testosterone)
|
Change from baseline to Week 4 and 12
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sexual activity
Time Frame: Change from baseline to Week 4 and 12
|
Sexual activity log (SAL, the number of satisfying sexual episodes over a 1-week period)
|
Change from baseline to Week 4 and 12
|
|
Sexual distress
Time Frame: Change from baseline to Week 4 and 12
|
the Personal Distress Scale (PDS, 0 [no distress] to 100 [maximum distress]).
|
Change from baseline to Week 4 and 12
|
|
Urogenital distress
Time Frame: Change from baseline to Week 4 and 12
|
Urogenital Distress Inventory (UDI-6, a 4-point scale, where a higher point means more symptoms)
|
Change from baseline to Week 4 and 12
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Mental Disorders
- Genital Diseases, Male
- Male Urogenital Diseases
- Pathological Conditions, Anatomical
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Genital Diseases, Female
- Sexual Dysfunction, Physiological
- Sexual Dysfunctions, Psychological
- Atrophy
- Dyspareunia
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Estrogens
- Estradiol
Other Study ID Numbers
Other Study ID Numbers
- 2020-003254-76
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.